Importantly, in these settings, the systemic administration of anti‐PD‐1 mAb along with intratumoral NK + anti‐NKG2A/Qa‐1b mAb therapy to only one of the tumors was capable of better controlling tumor growth in both the treated and the distant tumors (Fig 6A), significantly improving survival (Fig 6B). The gene discussed is KLRC1; the disease is neoplasm.